

# HALEON

Delivering better everyday health with humanity

Exceptional portfolio of category leading brands, trusted by consumers and recommended by experts



A global leader in consumer health

**#1**  
position in 5 global categories<sup>1</sup>


**£9.5bn**  
annual 2021 sales<sup>2</sup>

**22.8%**  
adjusted operating profit margin 2021<sup>2</sup>

**>100**  
markets served

**22,000**  
employees globally

Attractive geographic footprint, well placed for growth



Nicholas Hall's DB6 Consumer Healthcare (OTC/VMS) Database, 2020 Store and E commerce sales.  
Note: NewCo position in OTC/VMS. Brazil #4 overall, South Africa #2 overall, Poland #4 overall, Philippines #2 overall, Turkey #3 overall. MNC=Multi national Company. Germany is a statistical tie for #1.

Human understanding



Trusted science



Competitive advantage

- > A growing, £150 billion global healthcare sector
- > A management team with extensive experience across global FMCG and consumer health
- > Clear medium-term growth ambitions
  - 4-6% annual organic sales growth<sup>3</sup>
  - High cash conversion
  - Margin expansion while investing for growth
  - Disciplined capital allocation
- > Running a responsible business, integral to all we do

<sup>1</sup> Therapeutic Oral Health, Pain Relief, Respiratory, Vitamins, Minerals and Supplements and Digestive Health  
<sup>2</sup> Reflects Haleon basis of preparation of financial statements, as opposed to GSK plc basis of preparation of CH as a segment.  
<sup>3</sup> At constant exchange rates.  
Please read the cautionary statement regarding forward-looking statements and the definitions for non-IFRS measures on pages 4-7 of the Stock Exchange Announcement.